Company sells line of kidney stone diagnostic tests

December 20, 2007

Mission Pharmacal has sold the rights to its line of kidney stone diagnostics to Quest Diagnostics Inc. Products in the diagnostic line include UroRisk Diagnostic Profile, StoneRisk Diagnostic Profile, StoneTrack Diagnostic Monitoring Test, StoneRisk Citrate Test, and StoneRisk Cystine Tests. These tests are designed to help physicians diagnose patients who are symptomatic and, among those who previously had a stone, help in periodic evaluations of a patient’s propensity to form stones.

Mission Pharmacal has sold the rights to its line of kidney stone diagnostics to Quest Diagnostics Inc. Products in the diagnostic line include UroRisk Diagnostic Profile, StoneRisk Diagnostic Profile, StoneTrack Diagnostic Monitoring Test, StoneRisk Citrate Test, and StoneRisk Cystine Tests. These tests are designed to help physicians diagnose patients who are symptomatic and, among those who previously had a stone, help in periodic evaluations of a patient’s propensity to form stones.

Physicians will have continuity of service and uninterrupted availability of products during the transition. According to Misison Pharmacal, all products sold to Quest Diagnostics will be marketed with the current brand names, quality control, and up-to-date technology as those previously sold under Mission Pharmacal.